December 8, 2022 – Currently circulating mutant strains of influenza highlight the need for multi-target diagnostic tests. Two recently identified mutations in the matrix genes of the Human Influenza A virus have been reported to cause matrix gene target failure (MGTF) for several commercial diagnostic tests. Cepheid’s respiratory test design enables detection of these new variants, and with similar symptoms across various illnesses such as the flu, respiratory syncytial virus (RSV) disease, and COVID-19, an accurate and fast diagnosis is critical to patient care.
Variants of the (H1N1)pdm09 and A(H3N2) viruses containing matrix gene mutations are currently circulating around the world1. Recombination and other mutations of the viruses impact the performance of molecular diagnostic tests – which may lead to an increase in false negative test results. The greatest impact occurs in tests that detect only one genetic target of the influenza genome.
“In developing our portfolio of respiratory tests, we include multiple conserved gene targets to account for genetic drift within the influenza genome,” said David Persing, M.D., Ph.D., EVP and Chief Scientific Officer of Cepheid. “The resulting target redundancy mitigates the impact of mutational drift. Our three-gene target design for detection of influenza A reduces the risk of false-negative test results, even in the event of an MGTF.”
Cepheid’s respiratory tests all utilize a multi-target approach for the detection of influenza, providing target redundancy to mitigate the potential impact of genetic shift and drift on strain detection:
- Xpert Xpress Flu/RSV
- Xpert Xpress SARS-CoV-2/Flu/RSV^
- Xpert Xpress CoV-2/Flu/RSV plus^